- Details
- Ruchika Talwar interviews Brian Lane about a MUSIC collaborative study on same-day discharges for radical prostatectomy patients in Michigan. Dr. Lane discusses the study's findings, which show that only 2.8% of patients had same-day discharges between 2018 and 2022, despite efforts to increase uptake. The study demonstrates that same-day discharge is safe, with readmission rates comparable to one...
|
- Details
- Ruchika Talwar interviews David Friedlander about a primer on healthcare performance measurement developed in conjunction with the American Urological Association. Dr. Friedlander outlines five key takeaways from the document, including the purpose of performance measurement, categories and types of measures, contexts for their use, the measurement life cycle, and advanced topics. They discuss the...
|
- Details
- Ruchika Talwar interviews Laura Bukavina and Steven Leonard about their study on financial distress for genitourinary cancer patients. Using data from the CDC National Health Interview Survey, they explore how the rising costs of cancer drugs impact patients' financial well-being and access to care. The study reveals that GU cancer patients, particularly those with bladder and kidney cancer, strug...
|
- Details
- Ruchika Talwar interviews Apoorv Dhir and Rishi Sekar about their study on cancer-related financial hardship among cancer survivors. The researchers discuss findings from the HINTS-SEER survey, which reveals that 44% of cancer patients report some level of financial hardship. They highlight the importance of considering both individual and community-level factors in assessing financial burden. The...
|
- Details
- Arnav Srivastava discusses his research on out-of-pocket costs for prostate cancer screening follow-up among privately insured men. The study reveals that by 2020, 80% of patients face out-of-pocket expenses for diagnostic testing, with costs rising significantly over time. Patients undergoing both MRI and biopsy can expect to pay over $600. Dr. Srivastava highlights the potential implications, in...
|
- Details
- Daniel Joyce discusses the financial impact of advanced prostate cancer treatments on patients. He presents research showing significant out-of-pocket costs for oral cancer therapies, particularly for commercially insured patients. Dr. Joyce highlights disparities in costs based on factors like age, race, and income. He emphasizes the importance of addressing financial toxicity in patient care, no...
|
- Details
- Amy Reed discusses a study on diversity, equity, and inclusion in urolithiasis clinical trials over the past two decades. The research analyzes 180 trials, examining patient enrollment by race, ethnicity, and sex. Using a representation quotient, the study finds that white patients are adequately represented, Black patients are overrepresented, while Hispanic and mixed-race patients are underrepre...
|
- Details
- Mark Ball and Jessica Hsueh discuss a study on using GPT-4 for data extraction from renal surgery operative notes. The research compares GPT-4's performance to human-curated data across five variables: laterality, surgery type, approach, estimated blood loss, and ischemia time. Results show high accuracy for categorical variables but lower accuracy for continuous variables and heterogeneously writ...
|
- Details
- Valeska Halstead discusses a survey study examining pediatric urologists' perceptions of US News and World Report rankings. The study, with a 51% response rate from Society for Pediatric Urology members, reveals significant skepticism about the ranking system's validity. Notably, 86% of respondents support withdrawing from the rankings, with even 75% of those in top-10 institutions agreeing. Most...
|
- Details
- Anjali Kapur discusses a cost analysis comparing oral Phenazopyridine (Pyridium) to intravesical lidocaine for pain control during Botox injections for overactive bladder. The study finds that using Pyridium is less costly, saving about $98 per visit and potentially $24 million annually if widely adopted. Dr. Kapur highlights the high prevalence of overactive bladder and the increasing use of Boto...
|
